SciBase already received first order from Austria
Expansion to the wider DACH region has been one of the recently updated strategic focus areas for SciBase, as the company already had a strong position in Germany to build on. The now announced order was received very quickly, only 2-3 months after the first sales representative was hired in March, and we see it as a further signal of the competitiveness and attractiveness of the Nevisense product in the skin diagnostics market.
DACH expansion is off to a promising start, but US progress remains key
Rapid commercial progress in Austria is obviously positive for the company's investment case. The company is still cash flow negative and needs to prioritize its investments in areas that contribute most to achieving cash flow neutrality. While the expansion into the broader DACH region appears to be a good move from this perspective, we believe its importance to the company's overall investment case is currently more limited. SciBase needs to make a significant jump in revenues to reach cash flow neutrality, and we believe that progress in the very large US market is the key to achieving this. SciBase reports its Q1 results tomorrow and we have commented on our expectations for the report in our Q1 preview comment.
Scibase Holding
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen prob som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
Read more on company pageKey Estimate Figures18/04
2023 | 24e | 25e | |
---|---|---|---|
Omsättning | 23,2 | 31,9 | 50,4 |
tillväxt-% | 29,94 % | 37,33 % | 57,94 % |
EBIT (adj.) | −53,9 | −56,1 | −46,9 |
EBIT-% | −232,04 % | −175,89 % | −93,11 % |
EPS (adj.) | −0,51 | −0,24 | −0,20 |
Utdelning | 0,00 | 0,00 | 0,00 |
Direktavkastning | |||
P/E (just.) | - | - | - |
EV/EBITDA | - | - | - |